Reagents: TGFβ1 and Rhosin hydrochloride were from R&D Systems (Minneapolis, MN), CCG-1423, verteporfin, 3,3′-Diaminobenzidine (DAB) and picrosirius red (PSR) from Sigma Aldrich (St. Louis, MI). Antibodies were from the following sources: TAZ and TGFβ: Abcam (Cambridge, UK); MRTF-A: Cell Signaling Technologies (Danvers, MA); MRTF-B: Santa Cruz Biotech (Dallas, TX), tubulin: Sigma Aldrich (St. Louis, MI); active RhoA: New East Biosciences (King of Prussia, PA); Collagen IV: Southern Biotech (Birmingham, AL); horseradish peroxidase-coupled antibodies: Jackson ImmunoResearch Laboratories; Alexa 488 or 555-coupled antibodies: Invitrogen. 4,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) was from Lonza.
All methods applied in this study were performed in accordance with the relevant guidelines and regulations of Scientific Reports and the Keenan Research Centre/St. Michael’s Hospital.